

Technology Advisory Committee A Interests Register

Topic: Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]

Publication Date: 16 April 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
James Fotheringham	TAC A Member	Direct - Financial	James has supported systematic reviews in the area of uncontrolled and treatment-resistant hypertension for AstraZeneca, paid to his institution.	15/05/2024	It was agreed that James' declaration would not prevent him from participating in discussions on this appraisal.
Dominic Pivonka	TAC A Member	Direct - Financial Interests	Dominic's employer (AbbVie) has a treatment (mirvetuximab soravtansine) approved by the EMA and selected by NICE for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442. It is also being studied in other ovarian cancer indications, including a phase 3 study in platinum-sensitive ovarian cancer.	13/12/2024 18/07/2024 20/05/2024	It was agreed that Dominic's declaration would prevent him from participating in discussions on this appraisal.
Patrick de Barr	TAC A Member	Direct - Financial Interests	Patrick now works for GSK who produce niraparib another PARPi indicated in advanced ovarian cancer.	12/12/2024	It was agreed that Patrick's declaration would prevent him from participating in

					discussions on this appraisal.
Becky Pennington	TAC A Member	Indirect – Financial Interests	Becky's employer, the University of Sheffield, receives income from olaparib.	12/12/2024	It was agreed that Becky's declaration would not prevent her from participating in discussions on this appraisal.